This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2023 include: • Life sciences VC deal value in Q4 2023 totaled $6.6 billion, representing a 25.0% decrease from the prior quarter. Total deal value for 2023 reached $28.3 billion—a 23.2% decline from 2022 and the lowest annual total since 2019, indicating a return to pre-pandemic levels of activity as the VC environment has yet to fully regain its momentum.
Please see full publication below for more information.